MK-2866 (Ostarine)

Overview

MK-2866, commonly known as Ostarine or Enobosarm, is a non-steroidal selective androgen receptor modulator developed by GTx, Inc. (now Oncternal Therapeutics). It is the most extensively studied SARM in clinical development, having progressed through multiple phase II and phase III clinical trials for indications including cancer-related muscle wasting (cachexia) and stress urinary incontinence. Among all compounds classified as SARMs, Ostarine possesses the largest body of human clinical trial data, making it the benchmark against which other SARMs are typically compared.

GTx initiated the Ostarine program in the early 2000s, targeting the unmet medical need for agents that could prevent or reverse muscle loss in patients with serious illness without the virilizing side effects of traditional androgens. Cancer cachexia, a debilitating syndrome affecting up to 80% of patients with advanced cancer, was the primary indication. The condition involves progressive loss of skeletal muscle mass that cannot be fully reversed by nutritional support alone, and no FDA-approved pharmacotherapy existed for it at the time of Ostarine’s development.

Mechanism of Action

Ostarine binds to the androgen receptor with high affinity and selectivity. Like other non-steroidal SARMs, it produces a receptor conformation that differs from that induced by testosterone or DHT, leading to tissue-selective patterns of gene activation. In skeletal muscle, Ostarine activates AR-mediated transcriptional programs that promote protein synthesis, reduce protein degradation, and support myoblast differentiation and fusion. In prostate and seminal vesicle tissue, the compound shows substantially reduced activity compared to equivalent doses of testosterone.

The molecular basis for this tissue selectivity involves differential coregulator recruitment. In muscle tissue, the Ostarine-bound AR recruits coactivator proteins that drive anabolic gene transcription. In reproductive tissues, the same receptor complex preferentially recruits corepressors or fails to efficiently recruit the coactivators needed for full transcriptional activity. This model, while supported by in vitro evidence, continues to be refined as researchers identify the specific cofactors involved.

Ostarine also influences the Wnt signaling pathway, which plays a role in both muscle and bone homeostasis. In preclinical models, the compound increased bone mineral density and bone strength, suggesting potential utility in osteoporosis. Additionally, Ostarine has been shown to reduce body fat in animal models, likely through AR-mediated effects on adipocyte differentiation and lipolysis.

Research Summary

Ostarine has the most robust clinical dataset of any SARM. A phase II dose-finding study in 120 elderly men and postmenopausal women demonstrated dose-dependent increases in lean body mass over 12 weeks of treatment. The 3 mg daily dose group showed a statistically significant increase of approximately 1.4 kg in lean mass compared to placebo, with concurrent improvements in stair-climbing speed and power. No significant changes in prostate-specific antigen (PSA) were observed in male subjects, and virilization was not reported in female subjects.

The POWER 1 and POWER 2 phase III trials enrolled over 600 patients with non-small cell lung cancer undergoing chemotherapy. The primary endpoint was the proportion of patients who maintained or gained lean body mass while also improving physical function (measured by stair-climbing power). While both trials showed statistically significant increases in lean mass, neither achieved the coprimary endpoint of functional improvement. This failure to demonstrate functional benefit led to an FDA Complete Response Letter in 2018, effectively requiring additional data or a modified development strategy.

A separate development program targeted stress urinary incontinence in women, based on the hypothesis that AR-mediated strengthening of pelvic floor muscles could reduce incontinence episodes. Phase II results showed promising trends, but the program has not advanced to phase III as of the current date.

Pharmacokinetic data from clinical trials show that Ostarine has excellent oral bioavailability, a half-life of approximately 24 hours supporting once-daily dosing, and dose-proportional pharmacokinetics across the studied range. The compound is metabolized hepatically, primarily through phase I and phase II conjugation reactions.

Dosing in Published Research

MK-2866, also known as ostarine or enobosarm, is a selective androgen receptor modulator originally developed by GTx for muscle-wasting conditions. It is not an approved medicine and has no labeled dose. In its clinical trial program, the doses studied were 1 mg and 3 mg taken once daily: a Phase 2 cancer-cachexia trial used 1 mg or 3 mg over 16 weeks, and later Phase 3 trials used 3 mg daily. Despite measurable effects on lean body mass, the program did not lead to approval. These figures describe what was administered in those specific trials.

Safety and Side Effects

The clinical trial safety database for Ostarine is the most extensive for any SARM. In phase II and III studies, the compound was generally well tolerated. The most commonly reported adverse events included nausea, headache, fatigue, and back pain, occurring at rates similar to placebo in most studies. Liver function tests remained within normal limits for the majority of subjects, though isolated transaminase elevations were observed.

Hormonal effects were dose-dependent. At the 3 mg dose studied in clinical trials, modest reductions in total testosterone and SHBG were observed in male subjects, but these remained within the normal range for most participants. LH suppression was minimal at this dose. However, observational reports from the research community using higher doses (10 to 25 mg daily) describe more substantial HPG axis suppression, including symptomatic testosterone reduction requiring recovery periods of four to eight weeks after discontinuation.

HDL cholesterol reductions have been observed at higher doses, consistent with the class effect of androgenic compounds on hepatic lipase activity. The clinical significance of short-term HDL changes during limited-duration SARM use is uncertain but represents a theoretical cardiovascular concern with prolonged use.

No cases of virilization were reported in female subjects in clinical trials at the 1 to 3 mg dose range. At higher doses used in the research community, some female users have reported voice deepening and increased body hair, suggesting that tissue selectivity may diminish at supraphysiological exposure levels.

Current Research Status

Ostarine remains an investigational compound without FDA approval. Oncternal Therapeutics (the successor to GTx) has focused its pipeline on other programs, and the Ostarine development timeline is unclear. The compound is banned by WADA and has been the subject of numerous anti-doping rule violations in professional athletics. Despite its unapproved status, Ostarine is the most-cited SARM in the clinical literature and continues to serve as the reference standard for the SARM drug class. It is available through research chemical suppliers, and its clinical trial data provide a unique evidence base for understanding SARM pharmacology in human subjects.

Further reading: For a comparison of two related selective androgen receptor modulators, see RAD-140 vs LGD-4033: Comparing Two Researched SARMs.

Frequently Asked Questions